RXRX Stock Overview
Operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Recursion Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.29 |
| 52 Week High | US$15.74 |
| 52 Week Low | US$4.97 |
| Beta | 0.83 |
| 11 Month Change | -24.76% |
| 3 Month Change | -37.41% |
| 1 Year Change | -32.51% |
| 33 Year Change | -69.32% |
| 5 Year Change | n/a |
| Change since IPO | -79.90% |
Recent News & Updates
Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 12
Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts
Aug 01Recent updates
Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 12Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts
Aug 01Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery
Jun 24Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must
Jun 14Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%
May 22Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 12Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
Apr 10Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)
Mar 20Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely
Jan 31Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress
Jan 12Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues
Dec 09What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today
May 09We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth
Mar 01Shareholder Returns
| RXRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.1% | -0.3% | 2.6% |
| 1Y | -32.5% | 9.8% | 17.3% |
Return vs Industry: RXRX underperformed the US Biotechs industry which returned 9.8% over the past year.
Return vs Market: RXRX underperformed the US Market which returned 17.3% over the past year.
Price Volatility
| RXRX volatility | |
|---|---|
| RXRX Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RXRX's share price has been volatile over the past 3 months.
Volatility Over Time: RXRX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 500 | Chris Gibson | www.recursion.com |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer.
Recursion Pharmaceuticals, Inc. Fundamentals Summary
| RXRX fundamental statistics | |
|---|---|
| Market cap | US$1.77b |
| Earnings (TTM) | -US$374.93m |
| Revenue (TTM) | US$49.64m |
35.6x
P/S Ratio-4.7x
P/E RatioIs RXRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RXRX income statement (TTM) | |
|---|---|
| Revenue | US$49.64m |
| Cost of Revenue | US$322.10m |
| Gross Profit | -US$272.46m |
| Other Expenses | US$102.46m |
| Earnings | -US$374.93m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.33 |
| Gross Margin | -548.94% |
| Net Profit Margin | -755.37% |
| Debt/Equity Ratio | 5.3% |
How did RXRX perform over the long term?
See historical performance and comparison